Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- InspirMed Inc presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the International Society for Aerosols in Medicine Congress.
- InspirMed is a subsidiary of Taiwan Liposome Company (NASDAQ: TLC), specializing in developing inhalable liposome formulation programs for severe acute and chronic pulmonary diseases.
- Pharmacokinetic studies on inhalable liposomal GS-441524 (ISPM21) and inhalable liposomal hydroxychloroquine (ISPM19) showed significantly higher lung concentrations than their conventional counterparts, giving the candidates the potential as prophylaxis and treatment for COVID-19.
- GS-441524 is the main plasma metabolite of the antiviral prodrug remdesivir, which is approved in the US for COVID-19. GS-441524 holds several advantages over remdesivir, with better safety and efficacy profiles.
- Intratracheally administered ISPM21 had a long half-life of 22.8 hours, with significantly higher concentrations (over 200-fold) in the lung and comparable systemic exposure in the plasma than an equal dose of intravenously administered GS-441524 solution.
- At just 1% of the proposed oral dose of hydroxychloroquine to treat COVID-19, intratracheally administered ISPM19 had a longer half-life (around 2.5-fold) and higher exposure in the lung (~30-fold) than intravenously administered free hydroxychloroquine.
- ISPM19 nebulized into an aerosol exhibited a lung deposition rate (inhaled dose) of 26.67%.
- Price Action: TLC shares are up 3.3% at $4.4 during the premarket session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!